Background: Our objective is to explore the Peripheral Intravascular Lithotripsy (IVL) System in the treatment of calcific access vessels during thoracic endovascular aortic repair (TEVAR), endovascular aortic repair (EVAR), and transcatheter aortic valve intervention.
Methods: This retrospective, single-center study evaluated the outcomes of patients undergoing TEVAR, EVAR, or transcatheter aortic valve intervention with severe calcific arterial disease between July 2018 and August 2019. Maximum circumferential calcification, length of calcification, and inner/outer diameter measurements were collected with curved planar reformation by medical imaging software (Aquarius APS, TeraRecon, Foster City, Calif). Effective luminal gain was calculated using the minimal inner diameter and the largest bore passed within the vessel lumen. End points included technical success, mortality, adverse events, and requirement for bail out maneuvers. Technical success was defined as successful delivery and deployment of device or endograft.
Results: Nine patients were included (mean age, 79.3 ± 9.79 years; range, 59-97 years]). four transcatheter aortic valve replacement, one TEVAR, one EVAR, and three fenestrated EVAR. Six patients (66.7%) had more than one artery treated; the segments treated included common iliac artery (seven patients [77.8%]), the external iliac artery (seven patients [77.8%]), and the common femoral artery (one patient [11.1%]). The average inner iliac vessel diameter was 3.38 ± 0.99 mm (range, 1.87-4.72 mm). The average outside diameter of device introduced was 7.2 ± 0.94 (range, 6.3-8.8 mm) with 229% effective luminal gain. Technical success was achieved in 100% of cases with a 0% mortality. Adjunctive measures were needed in five cases (55.6%). One vessel perforation was controlled with covered stent (Viabahn; W. L. Gore & Associates, Flagstaff, Ariz) deployment. Dissection was identified in two cases requiring stent placement. Two cases required the use of the Terumo International Systems SOLOPATH Balloon Expandable TransFemoral System (Terumo Interventional Systems, Somerset, NJ). One case deployed a Viabahn stent applying the "crack and pave" technique.
Conclusions: As the population of the United States ages, calcified arterial disease will become an everyday clinical conundrum. Furthermore, the procedures for which the IVL system is geared toward facilitating will likely also increase in use. The IVL system is an additional tool in the vascular surgeon's armamentarium to obtain large-bore access in these calcified vessels. Further studies are needed to better assess the clinical effectiveness of the IVL system.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966846 | PMC |
http://dx.doi.org/10.1016/j.jvscit.2020.09.002 | DOI Listing |
Dalton Trans
January 2025
Department of Materials and Life Sciences, Faculty of Science and Technology, Sophia University, 7-1 Kioicho, Chiyoda-ku, Tokyo 102-8554, Japan.
The Ru(IV,IV), Ru(III,IV), and Ru(III,III) complexes with the doubly oxido- and/or hydroxido-bridged diamond core {Ru(μ-O(H))}, bridged by an η:η:μ-type bidentate sulfato ligand, [{Ru(L)}(μ-O)(μ-OSO)] ( = 1: [III,IV]; = 2: [IV,IV]), [{Ru(L)}(μ-O)(μ-OH)(μ-OSO)] ([III,IV_1H]), and [{Ru(L)}(μ-OH)(μ-OSO)] ([III,III_2H]) (L = ethylbis(2-pyridylmethyl)amine), were synthesised as ClO-salts, and their crystal and electronic structures investigated. The corresponding hydrogencarbonato-bridged Ru(III,III) complex, [{Ru(L)}(μ-OH)(μ-OCOH)] ([III,III(HCO3)_2H]), was also prepared and its crystallographic and electronic structures compared to those of the sulfato-bridged system, [III,III_2H]. All the sulfato-bridged complexes isolated were confirmed in the Pourbaix diagram, wherein the redox potential was plotted as a function of pH.
View Article and Find Full Text PDFSci Rep
December 2024
Environmental Systems Analysis, Chalmers University of Technology, Gothenburg, 412 96, Sweden.
J Soc Cardiovasc Angiogr Interv
November 2024
Division of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Background: Coronary artery disease (CAD) is the leading cause of death for women, yet they remain underrepresented in interventional CAD studies. Women have been shown to be at increased risk of mortality and major adverse events after percutaneous coronary intervention (PCI). The poorer outcomes are likely because women are typically diagnosed with CAD late, at an older age, with more comorbidities, and with more challenging anatomy including smaller vessels and higher prevalence of coronary artery calcification.
View Article and Find Full Text PDFSci Total Environ
December 2024
Flemish Institute for Technological Research (VITO), Unit Materials and Chemistry (MATCH), 2400 Mol, Belgium.
EuroIntervention
December 2024
St. Francis Hospital, Roslyn, NY, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!